Skip to content
  • Home
  • About
  • Contact
  • Services
  • Advertise with Us
US Pharma Marketing Logo

US Pharma Marketing

  • Industry Landscape
  • Your POV
  • Sponsored
  • Case Studies & Trends
  • Job & Career
  • Strategy & Execution
  • Digital Transformation
  • Regulatory Compliance
  • Leader Q&A

Industry Landscape

Articles under this category focus on macro trends, big pharma behavior, and annual outlooks.

How Lack of Physician Trust Delays Drug Adoption
Posted in
  • Industry Landscape

How Lack of Physician Trust Delays Drug Adoption

Physician trust is the cornerstone of successful drug adoption. Even therapies with superior efficacy or safety … How Lack of Physician Trust Delays Drug AdoptionRead more

by Jayshree Gondane•February 19, 2026February 19, 2026•0
Why Traditional Pharma Marketing No Longer Works
Posted in
  • Industry Landscape
  • Strategy & Execution

Why Traditional Pharma Marketing No Longer Works

The pharmaceutical industry has historically relied on a predictable playbook for bringing new therapies to market. … Why Traditional Pharma Marketing No Longer WorksRead more

by Jayshree Gondane•February 19, 2026February 19, 2026•0
How Marketing and Medical Affairs Can Work Better Together
Posted in
  • Industry Landscape
  • Strategy & Execution

How Marketing and Medical Affairs Can Work Better Together

In the modern pharmaceutical landscape, few internal relationships are as strategically important as the one between … How Marketing and Medical Affairs Can Work Better TogetherRead more

by Jayshree Gondane•February 18, 2026February 18, 2026•0
Why Pharma Companies Fail at Go-To-Market Execution
Posted in
  • Industry Landscape

Why Pharma Companies Fail at Go-To-Market Execution

In the pharmaceutical industry, few moments are as consequential as the transition from regulatory approval to … Why Pharma Companies Fail at Go-To-Market ExecutionRead more

by Jayshree Gondane•February 16, 2026February 16, 2026•0
How Sales Strategy Impacts Drug Adoption After Approval
Posted in
  • Industry Landscape

How Sales Strategy Impacts Drug Adoption After Approval

A drug can clear the U.S. Food and Drug Administration, secure a label, and still stall … How Sales Strategy Impacts Drug Adoption After ApprovalRead more

by Jayshree Gondane•February 16, 2026February 16, 2026•0
Why Drugs Fail After Phase I in the U.S. Market
Posted in
  • Industry Landscape
  • Regulatory Compliance

Why Drugs Fail After Phase I in the U.S. Market

In the United States, roughly 12 percent of drugs that enter clinical testing ultimately receive approval … Why Drugs Fail After Phase I in the U.S. MarketRead more

by Jayshree Gondane•February 16, 2026February 16, 2026•0
Why Clinical Trial Data Fails to Translate Into Market Success
Posted in
  • Industry Landscape
  • Strategy & Execution

Why Clinical Trial Data Fails to Translate Into Market Success

A therapy can clear Phase III, secure FDA approval, and generate headline optimism-only to miss revenue … Why Clinical Trial Data Fails to Translate Into Market SuccessRead more

by Jayshree Gondane•February 15, 2026February 15, 2026•0
How Poor Communication Between Teams Slows Drug Development
Posted in
  • Industry Landscape
  • Strategy & Execution

How Poor Communication Between Teams Slows Drug Development

Drug development is often framed as a scientific challenge. Breakthroughs hinge on molecular discovery, biomarker validation, … How Poor Communication Between Teams Slows Drug DevelopmentRead more

by Jayshree Gondane•February 15, 2026February 15, 2026•0
Why Pharma Companies Struggle With Trial Participant Retention
Posted in
  • Industry Landscape
  • Strategy & Execution

Why Pharma Companies Struggle With Trial Participant Retention

Nearly 30 percent of clinical trial participants withdraw before study completion in certain therapeutic areas, according … Why Pharma Companies Struggle With Trial Participant RetentionRead more

by Jayshree Gondane•February 15, 2026February 15, 2026•0
Pharma Marketing for Cardiovascular Drugs
Posted in
  • Industry Landscape

Pharma Marketing for Cardiovascular Drugs

Cardiovascular disease remains the world’s leading cause of death, driving sustained demand for cardiovascular therapeutics and … Pharma Marketing for Cardiovascular DrugsRead more

by Ritu Negi•February 14, 2026February 14, 2026•0

Posts pagination

Previous 1 … 9 10 11 … 24 Next

Recent Posts

  • Voice AI in Pharma Patient Engagement: How Smart Speakers Are Changing Adherence, Access, and the Next Front Door of Healthcare
  • How AI Is Automating Pharma Content Supply Chains and Rewiring the Economics of Medical, Legal, and Commercial Content
  • Predictive Analytics for Pharma Product Launch Forecasting: The Commercial Intelligence System Deciding Which Drug Launches Win
  • AI for Real-World Evidence in Pharma Marketing: How Commercial Teams Turn Clinical Data Into Market Access, Physician Trust, and Revenue Growth
  • Digital Twins in Pharmaceutical Manufacturing and Marketing: How Real-Time Simulation Is Redefining Drug Production, Commercial Strategy, and Market Advantage

Recent Comments

No comments to show.
Copyright © 2026 US Pharma Marketing.
Powered by WordPress and HybridMag.
  • Industry Landscape
  • Your POV
  • Sponsored
  • Case Studies & Trends
  • Job & Career
  • Strategy & Execution
  • Digital Transformation
  • Regulatory Compliance
  • Leader Q&A